AVROBIO Inc. announced the expansion of its senior management with three key hires. Nerissa Kreher, MD, MS, MBA joins as Chief Medical Officer for Rare Diseases, Kathryn McNaughton, PhD joins as Senior Vice President of Portfolio and Program Management and Richard Pfeifer, PhD, DABT joins as Director of Preclinical Development. Dr. Kreher is a pediatric endocrinologist with deep academic, clinical research and biotechnology industry experience. She has held leadership roles in both clinical development and medical affairs within private start-up biotechnology and large biotechnology companies focused on rare diseases. Most recently Dr. Kreher was the Global Head of Clinical and Medical Affairs at Zafgen Inc. Formerly she held roles of increasing responsibility at Shire, Alexion, Enobia Pharma, Genzyme and EMD Serono. Dr. McNaughton has 20 years of experience in the biotech industry encompassing R&D, Program Management and assessment of business development opportunities. She brings to AVROBIO deep expertise in global program leadership and orphan drug development, extending from the preclinical stage through commercialization. Dr. McNaughton was previously Vice President, R&D Pipeline Program Management at Synageva, and held roles of increasing responsibility at Shire and Praecis Pharmaceuticals. Dr. Pfeifer is a board-certified toxicologist with substantial industry experience providing technical and strategic leadership in toxicology and drug safety assessment across a broad range of therapeutic areas. His expertise spans small-molecule pharmaceuticals, biopharmaceuticals, vaccines, medical devices and gene therapies. Dr. Pfeifer was previously Head of Toxicology at Shire, and held roles of increasing responsibility at Wyeth Research, Ciba-Geigy Corp., and in the contract services industry. Dr. Pfeifer was also an Assistant Professor of Toxicology at Purdue University. Dr. Pfeifer pursued postdoctoral fellowships in Immunotoxicology at the Chemical Industry Institute of Toxicology and the National Institute of Environmental Health Sciences.
AVROBIO, Inc. is a gene therapy company. The Company is focused on developing potentially curative hematopoietic stem cells (HSC) gene therapies to treat patients with rare diseases following a single dose treatment regimen. The gene therapies that the Company is engaged in developing employ HSCs that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The Company's development focus has been on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies (ERTs). Its pipeline is comprised of three HSC gene therapy programs, which include AVR-RD-02 for the treatment of Gaucher disease type 1 and type 3; AVR-RD-03 for the treatment of Pompe disease, and AVR-RD-01 for the treatment of Fabry disease.
AVROBIO, INC. 
